

IVIG Market (Intravenous Immunoglobulin Market) by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome), Type (IgG, IgA, IgM, IgE, and IgD) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

<https://marketpublishers.com/r/G2C31F569BAEN.html>

Date: December 2016

Pages: 131

Price: US\$ 6,760.00 (Single User License)

ID: G2C31F569BAEN

Abstracts

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.

Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.

KEY BENEFITS

A comprehensive analysis of factors that drive and restrict the growth of the Global IVIG market. For instance, a large patient population and favorable government regulations will drive the Global IVIG market; however, the high cost of IVIG treatment and the associated risk of infection is likely to be a major restraint for the market.

The projections in the report are made by analyzing the current market trends and market potential for the period of 2014–2021, in terms of volume and value

The report covers a comprehensive analysis of all the geographic regions that help in determining the prevailing opportunities in these geographies. Government regulations regarding IVIG production and purification are discussed in detail

Competitive intelligence (of leading manufacturers of IVIG) helps in understanding the market scenario across geographies

SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies

The report provides a quantitative analysis of the current market and estimations through 2014-2021 that help in identifying the prevailing market opportunities.

KEY MARKET SEGMENT:

Global IVIG market is segmented based on the application, types and geography

MARKET BY APPLICATION

Hypogammaglobulinemia

Chronic Inflammatory demyelinating polyneuropathy (CIDP)

Immunodeficiency diseases

Congenital AIDS

Chronic Lymphocytic Leukaemia (CLL)

Myasthenia Gravis

Multifocal motor neuropathy

Idiopathic thrombocytopenic purpura (ITP)

Kawasaki disease

Guillain-Barre syndrome

Others

MARKET BY TYPE

IgG

IgA

IgM

IgE

IgD

MARKET BY GEOGRAPHY

North America

United States

Canada

Mexico

Europe

Germany

France

United Kingdom

Russia

Austria

Italy

Others

Asia-Pacific

India

China

Japan

Australia

Others

LAMEA

Latin America

Middle East

Africa

Contents

CHAPTER 1 INTRODUCTION

- 1.1 Report description
- 1.2 Key benefits
- 1.3 Key market segment
- 1.4 Research methodology
 - 1.4.1 Secondary Research
 - 1.4.2 Primary Research
 - 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 CXO perspective
- 2.2 Market beyond what to expect by 2026 (\$Million)
 - 2.2.1 Moderate growth scenario
 - 2.2.2 Rapid growth scenario
 - 2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

- 3.1 Market definition and scope
- 3.2 Overview of Intravenous Immunoglobulin (IVIG)
 - 3.2.1 Patented products
- 3.3 Epidemiology and economic burden of chronic conditions
- 3.4 Cost of side effects due to IVIG treatments
- 3.5 Key findings
 - 3.5.1 Top Factors Impacting global intravenous immunoglobulin market
 - 3.5.2 Top Investment pockets – Global Intravenous Immunoglobulin Market
- 3.6 Porter's five forces analysis
 - 3.6.1 Bargaining power of buyers (Low)
 - 3.6.2 Bargaining power of suppliers (Low)
 - 3.6.3 Threat of new entrants (low)
 - 3.6.4 Threat of substitutes (low)
 - 3.6.5 Intense competitive rivalry (moderate)
- 3.7 Value chain analysis
 - 3.7.1 Primary activities
 - 3.7.2 Support Activities

- 3.8 Market share analysis (2014)
- 3.9 Product scenario in IVIG market
- 3.10 Government regulations and reimbursements
 - 3.10.1 Intravenous Immunoglobulin (IVIG) regulations in United States and Europe
 - 3.10.2 Reimbursements Scenario
- 3.11 Indications for IVIG
 - 3.11.1 USFDA Indications
 - 3.11.2 European Medicine Agency
- 3.12 Component analysis of intravenous immunoglobulins (IgG)
 - 3.12.1 IgG1
 - 3.12.2 IgG2
 - 3.12.3 IgG3
 - 3.12.4 IgG4
- 3.13 Clinical trials
- 3.14 Patent analysis of IVIG market (2011-2014)
 - 3.14.1 Patent analysis by geography
 - 3.14.2 U.S. patent analysis
 - 3.14.3 Europe Patent Analysis
- 3.15 Market dynamics
 - 3.15.1 Drivers
 - 3.15.1.1 Rising Number of immunodeficiency Deficiency
 - 3.15.1.2 Increase in adoption of IVIG
 - 3.15.1.3 Increasing Number of People with Bleeding Disorders
 - 3.15.1.4 Rising Ageing Population
 - 3.15.2 Restraints
 - 3.15.2.1 Stringent Regulations
 - 3.15.2.2 High Cost of Therapy
 - 3.15.3 Opportunities
 - 3.15.3.1 Opportunities in emerging economies
 - 3.15.3.2 Development of cost effective therapeutics through large scale production

CHAPTER 4 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021

- 4.1 Hypogammaglobulinemia
- 4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
 - 4.1 Immunodeficiency diseases
 - 4.2 Congenital AIDS
- 4.3 Chronic Lymphocytic Leukemia
- 4.4 Myasthenia Gravis

- 4.5 Multifocal motor neuropathy
- 4.6 Primary Immune thrombocytopenia (ITP)
- 4.7 Kawasaki disease
- 4.8 Guillain-Barre syndrome
- 4.9 Others

CHAPTER 5 GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET BY PRODUCT TYPES

- 5.1 IgG
 - 5.1.1 Key Market Trends
 - 5.1.2 Clinical Interpretations
- 5.2 IgA
 - 5.2.1 Key Market Trends
 - 5.2.2 Clinical interpretation
- 5.3 IgM
 - 5.3.1 Key Market Trends
 - 5.3.2 Clinical Interpretation
- 5.4 IgE
 - 5.4.1 Key Market Trends
 - 5.4.2 Clinical Interpretation
- 5.5 IgD
 - 5.5.1 Key Market Trends

CHAPTER 6 GLOBAL IVIG MARKET, BY GEOGRAPHY, 2014-2021

- 6.1.1 Market size and forecast
- 6.2 North America
 - 6.2.1 U.S.
 - 6.2.1.1 Key Market Trends
 - 6.2.1.2 Market size and forecast
 - 6.2.2 Canada
 - 6.2.2.1 Key Market Trends
 - 6.2.2.2 Market size and forecast
 - 6.2.2.3 Mexico
 - 6.2.2.4 Key Market Trends
 - 6.2.2.5 Market Size and forecast
- 6.3 Europe
 - 6.3.1 Key market trends

6.3.2 Market size and forecast

6.3.3 U.K.

6.3.3.1 Key Market Trend

6.3.3.2 Market size and forecast

6.3.4 France

6.3.4.1 Key market trends

6.3.4.2 Market size and forecast

6.3.5 Germany

6.3.5.1 Market size and forecast

6.3.6 Italy

6.3.6.1 Market size and forecast

6.3.7 Austria

6.3.7.1 market size and forecast

6.3.8 Russia

6.3.8.1 market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends

6.4.2 Market size and forecast

6.4.3 Australia

6.4.3.1 Market size and forecast

6.4.4 Japan

6.4.4.1 Market size and forecast

6.4.5 India

6.4.5.1 Market size and forecast

6.4.6 China

6.4.6.1 Market size and forecast

6.4.7 Others

6.4.7.1 Market size and forecast

6.5 LAMEA

6.5.1 Key Market Trends

6.5.2 Market size and forecast

6.5.3 Latin America

6.5.3.1 Market size and forecast

6.5.4 Middle East

6.5.4.1 Market size and forecast

6.5.5 Africa

6.5.5.1 Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1 Biotest AG

- 7.1.1 Company overview
- 7.1.2 Biotest AG snapshot
- 7.1.3 Operating business segment overview
- 7.1.4 Financial performance
- 7.1.5 Strategic moves and developments
- 7.1.6 SWOT analysis of Biotest AG

7.2 Octapharma AG

- 7.2.1 Company overview
- 7.2.2 Octapharma AG snapshot
- 7.2.3 Operating business segment overview
- 7.2.4 Strategic moves and developments
- 7.2.5 SWOT analysis of Octapharma AG

7.3 Baxter International Inc.

- 7.3.1 Company overview
- 7.3.2 Baxter International Inc. snapshot
- 7.3.3 Operating business segments overview
- 7.3.4 Financial performance
- 7.3.5 Strategic moves and developments
- 7.3.6 SWOT analysis of Baxter International Inc.

7.4 LFB Biotechnologies

- 7.4.1 Company overview
- 7.4.2 LFB Biotechnologies snapshot
- 7.4.3 Operating business segment overview
- 7.4.4 Financial performance
- 7.4.5 SWOT analysis of LFB biotechnologies

7.5 China Biologics Products Inc.

- 7.5.1 Company overview
- 7.5.2 China Biologic Products Inc. Snapshot
- 7.5.3 Operating business segment overview
- 7.5.4 Financial performance
- 7.5.5 Strategic moves and developments
- 7.5.6 SWOT analysis of China Biologic Products Inc.

7.6 Grifols S.A.

- 7.6.1 Company overview
- 7.6.2 Grifols S.A Snapshot
- 7.6.3 Operating Business Segment Overview
- 7.6.4 Financial performance

- 7.6.5 Strategic moves and developments
- 7.6.6 SWOT analysis Grifols S.A.
- 7.7 Kedrion Biopharma
 - 7.7.1 Company overview
 - 7.7.2 Kedrion Biopharma. Snapshot
 - 7.7.3 Operating business segment overview
 - 7.7.4 Financial performance
 - 7.7.5 Strategic moves and developments
 - 7.7.6 SWOT Analysis of Kedrion Biopharma.
- 7.8 CSL Behring
 - 7.8.1 Company overview
 - 7.8.2 CSL Behring Snapshot
 - 7.8.3 Operating business segment overview
 - 7.8.4 Financial performance
 - 7.8.5 Strategic moves and developments
 - 7.8.6 SWOT ANALYSIS of CSL Behring
- 7.9 BDI Pharma Inc.
 - 7.9.1 Company overview
 - 7.9.2 BDI pharma Inc. Snapshot
 - 7.9.3 Operating business segment overview
 - 7.9.4 SWOT Analysis of BDI Pharma
- 7.10 Bayer Healthcare
 - 7.10.1 Company overview
 - 7.10.2 Business performance
 - 7.10.3 Strategic moves and developments
 - 7.10.4 SWOT analysis of Bayer Healthcare

List Of Tables

LIST OF TABLES

TABLE 1 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (\$MILLION)

TABLE 2 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)

TABLE 3 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (\$MILLION)

TABLE 4 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)

TABLE 5 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (\$MILLION)

TABLE 6 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)

TABLE 7 IVIG PRODUCTS COMMERCIALIZED IN MARKET

TABLE 8 USFDA INDICATIONS FOR IVIG

TABLE 9 EMA APPROVED INDICATIONS FOR IVIG

TABLE 10 IGG SUBCLASS

TABLE 11 FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS

TABLE 12 DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY

TABLE 13 CLINICAL TRIALS FOR INTRAVENOUS IMMUNOGLOBULIN (2011-2014)

TABLE 14 PATENT ANALYSIS- UNITED STATES (2010-2014)

TABLE 15 PATENT ANALYSIS- EUROPE (2010-2014)

TABLE 16 WORLD AGING POPULATION 2013

TABLE 17 GLOBAL IVIG MARKET, BY APPLICATION, 2014–2021, \$MILLION

TABLE 18 GLOBAL IVIG MARKET, BY APPLICATION, 2014–2021, (TONNE)

TABLE 19 COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

TABLE 20 HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 21 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 22 PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY

TABLE 23 IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 24 IVIG PRODUCTS FOR CONGENITAL AIDS

TABLE 25 CONGENITAL AIDS IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 26 CLL STATISTICS 2011-2014

TABLE 27 CHRONIC LYMPHOCYTIC LEUKAEMIA IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 28 MYASTHENIA GRAVIS IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 29 MULTIFOCAL MOTOR NEUROPATHY IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 30 ITP TREATMENT OPTIONS

TABLE 31 ITP IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 32 KAWASAKI DISEASE PATIENTS PER 100,000 CHILDREN IN 2010

TABLE 33 KAWASAKI DISEASE IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 34 GUILLAIN-BARRE SYNDROME IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 35 OTHER IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 36 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (\$MILLION)

TABLE 37 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (TONNE)

TABLE 38 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 39 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 40 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 41 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 42 HIGH PRIORITY INDICATIONS OF IVIG

TABLE 43 COST OF IVIG PRODUCTS IN UK

TABLE 44 PRODUCTS CONTAINING IVIG IN ITALIAN MARKET

TABLE 45 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (\$MILLION)

TABLE 46 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 47 IMMUNOGLOBULIN BRANDS AND ITS MANUFACTURERS

TABLE 48 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 49 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 50 BIOTEST AG SANPSHOT

TABLE 51 OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 52 OCTAPHARMA AG SNAPSHOT

TABLE 53 OCTAPHARMA AG OPERATING BUSNIESS OVERVIEW

TABLE 54 BAXTER INTERNATIONAL INC. SNAPSHOT

TABLE 55 OPERATING BUSINESS SEGMENTS OVERVIEW

TABLE 56 LFB BIOTECHNOLOGIES OPERATING SEGMENT OVERVIEW

TABLE 57 CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT

TABLE 58 CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT
OVERVIEW

TABLE 59 GRIFOLS S.A SNAPSHOT

TABLE 60 GRIFOLS S.A OPERATING SEGEMENTS

TABLE 61 KEDRION INC. SNAPSHOT

TABLE 62 KEDRION BIOPHARMA OPERATING SEGMENTS

TABLE 63 CSL BEHRING SNAPSHOT

TABLE 64 CSL BEHRING OPERATING SEGMENTS

TABLE 65 BDI PHARMA INC SNAPSHOT

TABLE 66 BDI PHARMA OPERATING SEGMENTS

TABLE 67 BAYER HEALTHCARE COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN MODERATE GROWTH SCENARIO

FIG. 2 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN RAPID GROWTH SCENARIO

FIG. 3 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN DIMINISHING GROWTH SCENARIO

FIG. 4 PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY

FIG. 5 TOP FACTORS IMPACTING GLOBAL IVIG MARKET (2015–2021)

FIG. 6 TOP INVESTMENT POCKETS – GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET

FIG. 7 PORTER’S FIVE FORCES ANALYSIS

FIG. 8 VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET

FIG. 9 MARKET SHARE ANALYSIS – GLOBAL IVIG MARKET 2014

FIG. 10 PATENT ANALYSIS BY GEOGRAPHY (2011-2014)

FIG. 11 U.S. PATENT ANALYSIS BY COMPANY (2011–2014)

FIG. 12 EUROPE PATENT ANALYSIS, BY COMPANY (2011–2014)

FIG. 13 INCIDENCES OF HAEMOPHILIA, 2010

FIG. 14 BIOTEST AG FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)

FIG. 15 BIOTEST AG FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)

FIG. 16 SWOT ANALYSIS OF BIOTEST AG

FIG. 17 SWOT ANALYSIS OF OCTAPHARMA AG

FIG. 18 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)

FIG. 19 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)

FIG. 20 SWOT ANALYSIS OF BAXTER INTERNATIONAL INC

FIG. 21 LFB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY PRODUCT SEGMENT (2013)

FIG. 22 LFB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)

FIG. 23 SWOT ANALYSIS OF LFB BIOTECHNOLOGIES

FIG. 24 CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE BY SEGMENTS

- FIG. 25 SWOT ANALYSIS OF CHINA BIOLOGIC PRODUCTS INC.
- FIG. 26 FINANCIAL OF GRIFOLS S.A BY GEOGRAPHY (2013)
- FIG. 27 FINANCIAL GRIFOLS S.A. BY PRODUCT GROUPS (2013)
- FIG. 28 SWOT ANALYSIS OF GRIFOLS S.A.
- FIG. 29 FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2013)
- FIG. 30 FINANCIAL KEDRION BIOPHARMA. BY PRODUCT GROUPS (2013)
- FIG. 31 SWOT ANALYSIS OF KEDRION BIOPHARMA
- FIG. 32 CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
- FIG. 33 CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
- FIG. 34 SWOT ANALYSIS OF CSL BEHRING
- FIG. 35 SWOT ANALYSIS OF BDI PHARMA
- FIG. 36 FINANCIAL REVENUE OF BAYER HEALTHCARE (2013 AND 2012)
- FIG. 37 FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2013
- FIG. 38 SWOT ANALYSIS OF BAYER HEALTHCARE

I would like to order

Product name: IVIG Market (Intravenous Immunoglobulin Market) by Application
(Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy,
Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic
Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency,
Guillain-Barre syndrome), Type (IgG, IgA, IgM, IgE, and IgD) - Global Opportunity
Analysis and Industry Forecast, 2014 - 2022

Product link: <https://marketpublishers.com/r/G2C31F569BAEN.html>

Price: US\$ 6,760.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/G2C31F569BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970